399 related articles for article (PubMed ID: 20596671)
1. Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed.
Cortes-Dericks L; Carboni GL; Schmid RA; Karoubi G
Int J Oncol; 2010 Aug; 37(2):437-44. PubMed ID: 20596671
[TBL] [Abstract][Full Text] [Related]
2. Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines.
Kitazono-Saitoh M; Takiguchi Y; Kitazono S; Ashinuma H; Kitamura A; Tada Y; Kurosu K; Sakaida E; Sekine I; Tanabe N; Tagawa M; Tatsumi K
Oncol Rep; 2012 Jul; 28(1):33-40. PubMed ID: 22562354
[TBL] [Abstract][Full Text] [Related]
3. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
[TBL] [Abstract][Full Text] [Related]
4. Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma.
Cioce M; Ganci F; Canu V; Sacconi A; Mori F; Canino C; Korita E; Casini B; Alessandrini G; Cambria A; Carosi MA; Blandino R; Panebianco V; Facciolo F; Visca P; Volinia S; Muti P; Strano S; Croce CM; Pass HI; Blandino G
Oncogene; 2014 Nov; 33(46):5319-31. PubMed ID: 24240684
[TBL] [Abstract][Full Text] [Related]
5. SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma.
Iwahori K; Serada S; Fujimoto M; Ripley B; Nomura S; Mizuguchi H; Shimada K; Takahashi T; Kawase I; Kishimoto T; Naka T
Int J Cancer; 2013 Jan; 132(2):459-71. PubMed ID: 22532243
[TBL] [Abstract][Full Text] [Related]
6. Intraoperative hyperthermic chemotherapy perfusion for malignant pleural mesothelioma: an in vitro evaluation.
Cameron RB; Hou D
J Thorac Cardiovasc Surg; 2013 Feb; 145(2):496-504. PubMed ID: 23174177
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy.
Fischer B; Frei C; Moura U; Stahel R; Felley-Bosco E
Lung Cancer; 2012 Oct; 78(1):23-9. PubMed ID: 22857894
[TBL] [Abstract][Full Text] [Related]
8. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
Jänne PA; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Ye Z; Monberg MJ; Obasaju CK;
J Thorac Oncol; 2006 Jul; 1(6):506-12. PubMed ID: 17409909
[TBL] [Abstract][Full Text] [Related]
9. MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma.
Yamamoto K; Seike M; Takeuchi S; Soeno C; Miyanaga A; Noro R; Minegishi Y; Kubota K; Gemma A
Oncol Rep; 2014 Dec; 32(6):2365-72. PubMed ID: 25231602
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDH(high)CD44(+) phenotype and sphere-forming capacity.
Cortes-Dericks L; Froment L; Boesch R; Schmid RA; Karoubi G
BMC Cancer; 2014 Apr; 14():304. PubMed ID: 24884875
[TBL] [Abstract][Full Text] [Related]
11. Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma.
Reid G; Pel ME; Kirschner MB; Cheng YY; Mugridge N; Weiss J; Williams M; Wright C; Edelman JJ; Vallely MP; McCaughan BC; Klebe S; Brahmbhatt H; MacDiarmid JA; van Zandwijk N
Ann Oncol; 2013 Dec; 24(12):3128-35. PubMed ID: 24148817
[TBL] [Abstract][Full Text] [Related]
12. Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed.
Hayashi H; Okamoto I; Ichikawa Y; Miyazaki M; Yoshioka H; Kunimasa K; Nakagawa K
Int J Clin Oncol; 2010 Oct; 15(5):497-9. PubMed ID: 20224880
[TBL] [Abstract][Full Text] [Related]
13. Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation.
Cioce M; Canino C; Goparaju C; Yang H; Carbone M; Pass HI
Cell Death Dis; 2014 Apr; 5(4):e1167. PubMed ID: 24722292
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.
Borchert S; Wessolly M; Schmeller J; Mairinger E; Kollmeier J; Hager T; Mairinger T; Herold T; Christoph DC; Walter RFH; Eberhardt WEE; Plönes T; Wohlschlaeger J; Aigner C; Schmid KW; Mairinger FD
BMC Cancer; 2019 Jan; 19(1):108. PubMed ID: 30700254
[TBL] [Abstract][Full Text] [Related]
15. [Prognosis related clinical and molecular factors in malignant pleural mesothelioma].
Wang YY; Zhang H; Bai H; Wang SH; Wu MN; An TT; Zhao J; Zhuo ML; Duan JC; Wang ZJ; Wang J
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):162-8. PubMed ID: 23856136
[TBL] [Abstract][Full Text] [Related]
16. Significance of osteopontin in the sensitivity of malignant pleural mesothelioma to pemetrexed.
Takeuchi S; Seike M; Noro R; Soeno C; Sugano T; Zou F; Uesaka H; Nishijima N; Matsumoto M; Minegishi Y; Kubota K; Gemma A
Int J Oncol; 2014 Jun; 44(6):1886-94. PubMed ID: 24714722
[TBL] [Abstract][Full Text] [Related]
17. Combination effect of photodynamic therapy using NPe6 with pemetrexed for human malignant pleural mesothelioma cells.
Maehara S; Usuda J; Ishizumi T; Ichinose S; Ohtani K; Inoue T; Imai K; Furumoto H; Kudo Y; Kajiwara N; Ohira T; Ikeda N
Int J Oncol; 2015 Feb; 46(2):741-9. PubMed ID: 25385189
[TBL] [Abstract][Full Text] [Related]
18. Mesothelioma-Associated Fibroblasts Modulate the Response of Mesothelioma Patient-Derived Organoids to Chemotherapy via Interleukin-6.
Cioce M; Gatti V; Napolitano F; Giorgiano NM; Marra A; Portella G; Fiorelli A; Pentimalli F; Fazio VM
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791392
[TBL] [Abstract][Full Text] [Related]
19. Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies.
Thellung S; Favoni RE; Würth R; Nizzari M; Pattarozzi A; Daga A; Florio T; Barbieri F
Curr Drug Targets; 2016; 17(7):824-49. PubMed ID: 26240051
[TBL] [Abstract][Full Text] [Related]
20. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
Zanellato I; Colangelo D; Osella D
Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
